Showing 5241-5250 of 5644 results for "".
- NuSight Medical Announces Issuance of U.S. Patent Covering the NuLids System for Treating Dry Eye Diseasehttps://modernod.com/news/nusight-medical-announces-issuance-of-u-s-patent-covering-the-nulids-system-for-treating-dry-eye-disease/2476697/NuSight Medical, a medical device company focused on the doctor directed, at-home treatment of dry eye disease, announced that the U.S. Patent Office has issued Patent No. 10,314,763, which is directed to methods related to the treatment of dry eye disease. U.S. Patent No. 10,314,763 cover
- AlpineInvestors to Make Strategic Growth Investments in Ohio Eye Care Businesseshttps://modernod.com/news/alpineinvestors-to-make-strategic-growth-investments-in-ohio-eye-care-businesses/2476694/Private equity firm Alpine Investors has invested in Ohio-based eye care business, Northeast Ohio Eye Surgeons (NEOES), including its subsidiary business, Ohio Eye Care Consultants (OECC). The two companies will together form a new ophthalmology platform for Alpine, and will continue to operate i
- RightEye, USA Baseball and Optometrists Team Up to Improve Players’ Athletic Abilities Through Sports Visionhttps://modernod.com/news/righteye-usa-baseball-and-optometrists-team-up-to-improve-players-athletic-abilities-through-sports-vision/2476677/RightEye announced that it is working with USA Baseball for the third consecutive year to provide baseline sports vision assessment to all athletes entering the Prospect Development Pipeline (PDP), a collaboration bet
- Ocutech Adds 3x and 5.5x Power Options for the Falcon Autofocus Bioptichttps://modernod.com/news/ocutech-adds-3x-and-5-5x-power-options-for-the-falcon-autofocus-bioptic/2476672/The Ocutech Falcon Autofocus Bioptic self-focusing low vision telescope is now available in 3x, 4x and 5.5x powers. Released in late 2018 in its original 4x power, the Falcon Autofocus bioptic is now being prescribed in the US and in 11 foreign countries. The Falcon’s Time-of-Flight (ToF)
- Harrow Health to Locate Headquarters in Nashville, Tennesseehttps://modernod.com/news/harrow-health-to-locate-headquarters-in-nashville-tennessee/2476667/Harrow Health announced that the company will relocate its headquarters from San Diego to Nashville, Tennessee. “From our new home in Nashville, our team will continue to start, finance and grow pharmaceutical companies that will develop innovative, affordable and accessible medicines to s
- Be The Match BioTherapies and TrakCel Partner to Standardize Cell and Gene Therapy Supply Chain Solutionshttps://modernod.com/news/be-the-match-biotherapies-and-trakcel-partner-to-standardize-cell-and-gene-therapy-supply-chain-solutions/2476662/Be The Match BioTherapies and TrakCel, a software developer for cell and gene therapy supply chain tracking and orchestration systems, announced a collaboration that will provide integrated solutions for companies develo
- Eyepromise Introduces Screen Shield Pro All-Natural Eye Vitamin for Screen Time Protection for Adultshttps://modernod.com/news/eyepromise-introduces-screen-shield-pro-all-natural-eye-vitamin-for-screen-time-protection-for-adults/2476661/EyePromise announced the introduction of Screen Shield Pro to its premium eye vitamin line. EyePromise’s Screen Shield Pro is designed to protect and relieve the associated symptoms of digital eye strain of adults (ages 18 and up) who spend 8+ hours staring at digital screens while working, gami
- Ribomic Announces Positive Topline Results from the Phase 1/2a Clinical Trial of RBM-007 (SUSHI Study) in Subjects with Wet AMDhttps://modernod.com/news/ribomic-announces-positive-topline-results-from-the-phase-1-2a-clinical-trial-of-rbm-007-sushi-study-in-subjects-with-wet-amd/2476656/Ribomic announced positive topline results from its SUSHI study, a phase 1/2a single ascending dose clinical study of RBM-007, anti-FGF2 aptamer, in nine subjects with wet age-related macular degeneration (AMD). The SUSHI study achiev
- Pre-Pilot Clinical Trial from Ocutrx Vision Technologies Yields Exciting Results for Patients with AMDhttps://modernod.com/news/pre-patient-trial-from-ocutrx-vision-technologies-yields-exciting-results-for-patients-with-amd/2476659/Ocutrx Vision Technologies announced the results of the first pre-pilot clinical trial for the company’s Oculenz AR glasses. In the single arm crossover study of subjects with advanced macular degeneration, the Oculenz AR glasses significantly improved the ability of subjects to read small letter
- Glaucoma Drugs Continue to Battle for Market Sharehttps://modernod.com/news/glaucoma-drugs-continue-to-battle-for-market-share/2476655/Two new glaucoma drugs introduced in the US in 2018 continue to battle for market share. Rhopressa, from Aerie Pharmaceuticals, got out of the gate faster than Vyzulta from Bausch Health. The growth rate for both drugs slowed in the first quarter of 2019, which is normal after a product launch, a